Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population

We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions. Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.

NCT Number	NCT05837884
Lead Sponsor	Tel-Aviv Sourasky Medical Center Collaborators: Dana-Farber Cancer Institute
Conditions	Healthy
Enrollment	2,000 participants
Start Date	2023-09-05
Primary Completion	2027-06 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-11